Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

Ruben A. Mesa; Catriona Jamieson; Ravi Bhatia; Michael W. Deininger; Christopher D. Fletcher; Aaron T. Gerds; Ivana Gojo; Jason Gotlib; Krishna Gundabolu; Gabriela Hobbs; Brandon McMahon; Sanjay R. Mohan; Stephen Oh; Eric Padron; Nikolaos Papadantonakis; Philip Pancari; Nikolai Podoltsev; Raajit Rampal; Erik Ranheim; Vishnu Reddy; Lindsay A.M. Rein; Bart Scott; David S. Snyder; Brady L. Stein; Moshe Talpaz; Srdan Verstovsek; Martha Wadleigh; Eunice S. Wang; Mary Anne Bergman; Kristina M. Gregory; Hema Sundar

doi:10.6004/jnccn.2017.0157

Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D. Fletcher, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu ReddyLindsay A.M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, Hema Sundar

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

117 Scopus citations

Abstract

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

Original language	English (US)
Pages (from-to)	1193-1207
Number of pages	15
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	15
Issue number	10
DOIs	https://doi.org/10.6004/jnccn.2017.0157
State	Published - Oct 1 2017

Funding

This activity is supported by educational grants from Astellas, AstraZeneca, Celldex Therapeutics, Clovis Oncology, Genomic Health, Inc., Kyowa Hakko Kirin, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, and NOVOCURE. This activity is supported by an independent educational grant from Merck Co., Inc.

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2017.0157

Cite this

Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., Gojo, I., Gotlib, J., Gundabolu, K., Hobbs, G., McMahon, B., Mohan, S. R., Oh, S., Padron, E., Papadantonakis, N., Pancari, P., Podoltsev, N., Rampal, R., Ranheim, E., ... Sundar, H. (2017). Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(10), 1193-1207. https://doi.org/10.6004/jnccn.2017.0157

@article{962dbb39acb74eb2a47b65b740d3a7f3,

title = "Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines",

abstract = "Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.",

author = "Mesa, {Ruben A.} and Catriona Jamieson and Ravi Bhatia and Deininger, {Michael W.} and Fletcher, {Christopher D.} and Gerds, {Aaron T.} and Ivana Gojo and Jason Gotlib and Krishna Gundabolu and Gabriela Hobbs and Brandon McMahon and Mohan, {Sanjay R.} and Stephen Oh and Eric Padron and Nikolaos Papadantonakis and Philip Pancari and Nikolai Podoltsev and Raajit Rampal and Erik Ranheim and Vishnu Reddy and Rein, {Lindsay A.M.} and Bart Scott and Snyder, {David S.} and Stein, {Brady L.} and Moshe Talpaz and Srdan Verstovsek and Martha Wadleigh and Wang, {Eunice S.} and Bergman, {Mary Anne} and Gregory, {Kristina M.} and Hema Sundar",

note = "Publisher Copyright: {\textcopyright} JNCCN - Journal of the National Comprehensive Cancer Network.",

year = "2017",

month = oct,

day = "1",

doi = "10.6004/jnccn.2017.0157",

language = "English (US)",

volume = "15",

pages = "1193--1207",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "10",

}

Mesa, RA, Jamieson, C, Bhatia, R, Deininger, MW, Fletcher, CD, Gerds, AT, Gojo, I, Gotlib, J, Gundabolu, K, Hobbs, G, McMahon, B, Mohan, SR, Oh, S, Padron, E, Papadantonakis, N, Pancari, P, Podoltsev, N, Rampal, R, Ranheim, E, Reddy, V, Rein, LAM, Scott, B, Snyder, DS, Stein, BL, Talpaz, M, Verstovsek, S, Wadleigh, M, Wang, ES, Bergman, MA, Gregory, KM & Sundar, H 2017, 'Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 10, pp. 1193-1207. https://doi.org/10.6004/jnccn.2017.0157

TY - JOUR

T1 - Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

AU - Mesa, Ruben A.

AU - Jamieson, Catriona

AU - Bhatia, Ravi

AU - Deininger, Michael W.

AU - Fletcher, Christopher D.

AU - Gerds, Aaron T.

AU - Gojo, Ivana

AU - Gotlib, Jason

AU - Gundabolu, Krishna

AU - Hobbs, Gabriela

AU - McMahon, Brandon

AU - Mohan, Sanjay R.

AU - Oh, Stephen

AU - Padron, Eric

AU - Papadantonakis, Nikolaos

AU - Pancari, Philip

AU - Podoltsev, Nikolai

AU - Rampal, Raajit

AU - Ranheim, Erik

AU - Reddy, Vishnu

AU - Rein, Lindsay A.M.

AU - Scott, Bart

AU - Snyder, David S.

AU - Stein, Brady L.

AU - Talpaz, Moshe

AU - Verstovsek, Srdan

AU - Wadleigh, Martha

AU - Wang, Eunice S.

AU - Bergman, Mary Anne

AU - Gregory, Kristina M.

AU - Sundar, Hema

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

AB - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

UR - http://www.scopus.com/inward/record.url?scp=85030841097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030841097&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0157

DO - 10.6004/jnccn.2017.0157

M3 - Review article

C2 - 28982745

AN - SCOPUS:85030841097

SN - 1540-1405

VL - 15

SP - 1193

EP - 1207

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 10

ER -

Myeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelines

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this